SAN DIEGO--(BUSINESS WIRE)--iTherX Pharmaceuticals Inc, a privately held biopharmaceutical company, today announced that it has appointed a Scientific and Clinical Advisory Board to assist the company in the development of its novel therapeutic agents for Hepatitis C. iTherX is pioneering the introduction of a novel class of antivirals called entry inhibitors. These agents prevent the first step in virus infection: fusion with and entry into the liver cell. The company has identified unique molecular targets for Hepatitis C, and is developing two distinct series of therapeutics: HepaBloc™, which targets host cell proteins involved in infection, and ViraBloc™, which targets the viral envelope. In addition, iTherX scientists have identified a novel host cell receptor required for virus entry and will begin drug development against this target.
